ABSTRACT
4-aminopyridine (4AP) is a potassium (K+) channel blocker used clinically to improve walking in people with multiple sclerosis (MS). 4AP binds to exposed K+ channels in demyelinated axons, reducing the leakage of intracellular K+ and enhancing impulse conduction. Multiple derivatives of 4AP capable of blocking K+ channels have been reported including three radiolabeled with positron emitting isotopes for imaging demyelinated lesions using positron emission tomography (PET). However, there remains a demand for novel molecules with suitable physicochemical properties and binding affinity that can potentially be radiolabeled and used as PET radiotracers. In this study, we introduce 3-fluoro-5-methylpyridin-4-amine (5Me3F4AP) as a novel trisubstituted K+ channel blocker with potential application in PET. 5Me3F4AP has comparable potency to 4AP and the PET tracer 3-fluoro-4-aminopyridine (3F4AP). Compared to 3F4AP, 5Me3F4AP exhibits comparable basicity (pKa = 7.46 ± 0.01 vs. 7.37 ± 0.07, P-value = 0.08), greater lipophilicity (logD = 0.664 ± 0.005 vs. 0.414 ± 0.002, P-value < 0.0001) and higher permeability to an artificial brain membrane (Pe = 88.1 ± 18.3 vs. 31.1 ± 2.9 nm/s, P-value = 0.03). 5Me3F4AP is also more stable towards oxidation in vitro by the cytochrome P450 enzyme CYP2E1 (IC50 = 36.2 ± 2.5 vs. 15.4 ± 5.1, P-value = 0.0003); the enzyme responsible for the metabolism of 4AP and 3F4AP. Taken together, 5Me3F4AP has promising properties as a candidate for PET imaging warranting additional investigation.
Subject(s)
Positron-Emission Tomography , Potassium Channel Blockers , Potassium Channel Blockers/pharmacology , Potassium Channel Blockers/chemistry , Humans , Positron-Emission Tomography/methods , 4-Aminopyridine/pharmacology , 4-Aminopyridine/chemistry , 4-Aminopyridine/analogs & derivatives , Amifampridine/metabolismABSTRACT
Using biocompatible polymer nanofibrous conduits with a controlled drug delivery have attracted much attention for peripheral nerve regeneration. This work was aimed at preparing electrospun poly (l-lactide-co-D, l-lactide) (PLDLLA) containing multi-walled carbon nanotubes (MWCNTs) and 4-aminopyridine (4-AP)-loaded molecularly imprinted nanoparticles (MIP4-AP) as well as evaluating their performance in in vitro and in vivo assessments. After synthesis of MIP4-AP based on poly (methacrylic acid) with imprinting factor of 1.78, it was incorporated into the PLDLLA/MWCNTs nanofibers to optimize. By adjusting the process variables, the average diameter and electrical conductivity of the nanofibrous sample were 92 nm and 2870 × 10-7 S cm-1, respectively. Afterward, 4-AP release of the optimum sample showed the presence of MIP4-AP leading to initial burst release decrease and plateau level postpone up to 96 h. Moreover, the culture results of PC12 as neuroblastoma cell line on optimal PLDLLA/MWCNTs/MIP4-AP nanofibrous sample revealed the highest cell proliferation without cytotoxicity compared to neat nanofibers. Eventually, the animal model experiment exhibited that the conductive conduit based on the optimum sample was able to repair the rat's sciatic nerve after four weeks in accordance with sciatic function index and histological studies.
Subject(s)
4-Aminopyridine/chemistry , Methacrylates/chemistry , Molecular Imprinting , Nanofibers/chemistry , Nerve Regeneration/physiology , Peripheral Nerves/physiology , Polyesters/chemistry , Tissue Engineering , Adsorption , Animals , Cell Death , Cell Proliferation , Cell Survival , Electric Conductivity , Nanofibers/ultrastructure , Nanoparticles/chemistry , Nanoparticles/ultrastructure , Nanotubes, Carbon/chemistry , Nanotubes, Carbon/ultrastructure , PC12 Cells , Rats , Rats, WistarABSTRACT
This work investigated the modification of low-methoxy pectin with stearic anhydride through microwave action with 4-dimethylaminopyridine as catalyst. Fourier transform infrared spectroscopy (FTIR) and X-ray photoelectron spectroscopy (XPS) analyses indicated that stearic acid was grafted on the pectin through esterification reaction, with the maximum stearic acid grafting ratio (SGR) of 10.7% for the modified pectin. The introduction of stearic acid was shown to significantly improve the emulsifying activity and stability of pectin. Composite films were prepared by blending the modified pectins and chitosan, and compared with the contact angle of 65.3° for the film with native low-methoxy pectin (PC0), the films with modified pectins showed a significant angle increase, with the highest contact angle reaching 101.9°, indicating a hydrophobic surface. Moreover, an appropriate amount of aliphatic chains could improve the tensile strength and elongation at break of the composite films due to the "anchoring effect".
Subject(s)
Edible Films , Esters/chemistry , Pectins/chemistry , Stearic Acids/chemistry , 4-Aminopyridine/analogs & derivatives , 4-Aminopyridine/chemistry , Catalysis , Emulsions , Esterification , Hydrophobic and Hydrophilic Interactions , Microwaves , Tensile StrengthABSTRACT
Life emerges from complicated and sophisticated chemical networks comprising numerous biomolecules (e.g., nucleic acids, proteins, sugars, and lipids) and chemical reactions catalyzed by enzymes. Dysregulation of these chemical networks is linked to the emergence of diseases. Our research goal is to develop abiotic chemical catalysts that can intervene into life's chemical networks by complementing, surrogating, or exceeding enzymes in living cells or multicellular organisms such as animals or plants. Mending dysregulated networks in pathological states by the chemical catalysts will lead to a new medicinal strategy, catalysis medicine. This research direction will also advance catalysis science, because highly active and selective chemical catalysts must be developed to promote the intended reactions in a complex mixture of life in aqueous solution at body temperature.Epigenetics exists at the crossroads of chemistry, biology, and medicine and is a suitable field to pursue this idea. Post-translational modifications (PTMs) of histones epigenetically regulate chromatin functions and gene transcription and are intimately related to various diseases. Investigating the functions and cross-talk of histone PTMs is crucial for mechanistic elucidation of diseases and their treatments. We launched a program to develop chemical catalysts enabling endogenous histone modifications in living cells without relying on enzymes. We reported two types of chemical catalyst systems so far for synthetic histone acylation. The first system comprised a DNA-binding oligo-4-dimethylaminopyridine (DMAP) catalyst and a phenyl ester acyl donor, PAc-gly. This system promoted histone hyperacetylation in Xenopus laevis sperm chromatin. Using the thus-synthesized hyperacetylated sperm chromatin, we found a novel relationship between histone acetylation and DNA replication. The second system involved a histone-binding catalyst, LANA-DSH, composed of a catalytic motif (DSH) and a histone-binding peptide ligand (LANA), and thioester acyl donors, including endogenous acyl-CoA. This system regioselectively (i.e., selectively to a lysine residue at a specific position) acylated lysine 120 of histone H2B (H2BK120), a lysine residue proximal to the DSH motif defined by binding of the LANA ligand to a nucleosome substrate. This catalyst system was optimized to achieve H2BK120-selective acetylation in living cells without genetic manipulation. The synthetically introduced H2BK120Ac inhibited enzyme-catalyzed ubiquitination at the same lysine residue, acting as a protecting group. H2BK120Ub is a mark recognized by methyltransferase that plays an essential role in mixed-lineage leukemia (MLL)-rearranged leukemia, suggesting the potential of the catalyst system as an epigenetic tool and a cancer therapy. We also discuss the prospects of chemical catalyst-promoted synthetic epigenetics for future PTM studies and therapeutic uses.
Subject(s)
4-Aminopyridine/analogs & derivatives , DNA/chemistry , Esters/chemistry , Histones/chemistry , Peptides/chemistry , Sulfhydryl Compounds/chemistry , 4-Aminopyridine/chemistry , Animals , Catalysis , Epigenesis, Genetic/genetics , Histones/genetics , Histones/metabolism , Humans , Protein Processing, Post-TranslationalABSTRACT
Signal Amplification by Reversible Exchange (SABRE) technique enables nuclear spin hyperpolarization of wide range of compounds using parahydrogen. Here we present the synthetic approach to prepare 15 N-labeled [15 N]dalfampridine (4-amino[15 N]pyridine) utilized as a drug to reduce the symptoms of multiple sclerosis. The synthesized compound was hyperpolarized using SABRE at microtesla magnetic fields (SABRE-SHEATH technique) with up to 2.0 % 15 N polarization. The 7-hour-long activation of SABRE pre-catalyst [Ir(IMes)(COD)Cl] in the presence of [15 N]dalfampridine can be remedied by the use of pyridine co-ligand for catalyst activation while retaining the 15 N polarization levels of [15 N]dalfampridine. The effects of experimental conditions such as polarization transfer magnetic field, temperature, concentration, parahydrogen flow rate and pressure on 15 N polarization levels of free and equatorial catalyst-bound [15 N]dalfampridine were investigated. Moreover, we studied 15 N polarization build-up and decay at magnetic field of less than 0.04â µT as well as 15 N polarization decay at the Earth's magnetic field and at 1.4â T.
Subject(s)
4-Aminopyridine/chemistry , 4-Aminopyridine/chemical synthesis , Magnetic Fields , Magnetic Resonance Spectroscopy , Nitrogen IsotopesABSTRACT
The current study involves development of novel tamarind seed gum - alginate complex microspheres for sustained release of dalfampridine by using Central Composite design in combination with response surface methodology. Polymer ratio (A), agitation speed (B) and concentration of CaCl2 (C) were selected as independent variables. Dalfampridine loaded microspheres are prepared by ionotropic gelation technique and were evaluated for responses. The software numerical optimization process, surface and contour plots predicted the level of independent variables A, B and C (2.6, 800.412 rpm and 1.1%w/w respectively), for maximum response of drug entrapment efficiency (86.09%), controlled release of drug at 1 h, 6 h, 12 h (29.84%, 67.92%, 86.42%) and optimized particle size (613.212 µm) respectively. Low magnitude of relative error for the optimized formulation confirms the validation of model. Optimized formulation was characterized for compatibility by Fourier Transform infrared spectroscopy and Differential scanning calorimetry. The drug release data was best fitted by first order and Higuchi square root model with non-Fickian diffusion kinetics. Therefore, such an attempt of fabrication of dalfampridine multi-particulates system by using tamarind seed gum and sodium alginate may be useful in a better way, for sustaining the release of drug over 12 h.
Subject(s)
4-Aminopyridine/chemistry , Alginates/chemistry , Drug Carriers/chemistry , Plant Gums/chemistry , Seeds/chemistry , Tamarindus/chemistry , 4-Aminopyridine/pharmacology , Chemistry, Pharmaceutical , Delayed-Action Preparations/chemistry , Diffusion , Drug Liberation , Hydrogels/chemistry , Kinetics , Microspheres , Models, Chemical , Particle Size , Surface PropertiesABSTRACT
Introduction: Multiple sclerosis (MS) is a demyelinating disease, causing axonal damage and disability. Dalfampridine (DAL) is an extended-release formulation of 4-aminopyridine (4AP) and broad-spectrum voltage-dependent potassium channel blocker that is reported to improve motor, visual and cognitive functions. Furthermore, it is presently the only approved drug for walking impairment in MS. Areas covered: Herein, the authors evaluate DAL as a relapsing-remitting MS treatment, reporting and commenting on all aspects of the drug including its chemistry, safety, pharmacokinetics, and cost-effectiveness. A bibliographic search was performed on PubMed using the terms 'dalfampridine OR fampridine OR 4-aminopyridine'. Expert opinion: Evidence from post-marketing studies suggests that DAL, consistent with the effects of 4AP, may not only improve walking speed, but also arm function, fatigue, mood and cognition through restored nerve conduction in central nervous system demyelinated areas. Long-term safety data confirm that the approved dose of 10 mg twice daily is generally well tolerated. However, despite the reported efficacy, the extent of the benefits is limited in real life activities, although significant improvements have been demonstrated in the clinical setting. Patients often complain of side effects (such as cramps and painful paraesthesia) or lack of efficacy. Also, its considerably higher pricing in comparison to 4AP represents an important limitation.
Subject(s)
4-Aminopyridine/therapeutic use , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Potassium Channel Blockers/therapeutic use , 4-Aminopyridine/adverse effects , 4-Aminopyridine/chemistry , 4-Aminopyridine/pharmacokinetics , Clinical Trials as Topic , Cognitive Dysfunction/complications , Cost-Benefit Analysis , Databases, Factual , Fatigue/complications , Half-Life , Humans , Multiple Sclerosis, Relapsing-Remitting/economics , Potassium Channel Blockers/adverse effects , Potassium Channel Blockers/chemistry , Potassium Channel Blockers/pharmacokinetics , Seizures/etiology , Treatment OutcomeABSTRACT
We report a novel approach for generating nanosized DNA hollow spheres (HSs) using enzymatically produced DNA microsponges in a self-templating manner. In previous studies, preparation of DNA nanostructures with specified functions required multiple complicated steps. In this study, however, a simple treatment with the nucleophilic agent 4-dimethylaminopyridine (DMAP) enabled a gradual disentanglement of DNA in microsponges by electrostatic interactions between DMAP and DNA, and the DNA underwent a reassembly process to generate hollow shell structures without denaturation/annealing by thermal cycling. In addition, this synthetic process was conducted in a water-based system without organic solvents, enabling the synthesis of biologically and environmentally friendly products. Based on the benefits of hollow shell structures, which include their high surface-to-volume ratio and ability to encapsulate small molecules, we envision that this simple approach for synthesizing DNA HSs will provide a new platform for maximizing their potential use in drug delivery and bio-imaging.
Subject(s)
DNA/chemistry , Nanospheres/chemistry , 4-Aminopyridine/analogs & derivatives , 4-Aminopyridine/chemistry , Gold/chemistry , Molecular Dynamics Simulation , Nanospheres/ultrastructureABSTRACT
Peripheral nerve injury accounts for roughly 2.8% of all trauma patients with an annual cost of 7 billion USD in the U.S. alone. Current treatment options rely on surgical intervention with the use of an autograft, despite associated shortcomings. Engineered nerve guidance conduits, stem cell therapies, and transient electrical stimulation have reported to increase speeds of functional recovery. As an alternative to the conduction effects of electrical stimulation, we have designed and optimized a nerve guidance conduit with aligned microchannels for the sustained release of a small molecule drug that promotes nerve impulse conduction. A biodegradable chitosan structure reinforced with drug-loaded halloysite nanotubes (HNT) was formed into a foam-like conduit with interconnected, longitudinally-aligned pores with an average pore size of 59.3⯱â¯14.2⯵m. The aligned composite with HNTs produced anisotropic mechanical behavior with a Young's modulus of 0.33⯱â¯0.1â¯MPa, very similar to that of native peripheral nerve. This manuscript reports on the sustained delivery of 4-Aminopyridine (4AP, molecular weight 94.1146â¯g/mol), a potassium-channel blocker as a growth factor alternative to enhance the rate of nerve regeneration. The conduit formulation released a total of 30⯱â¯2% of the encapsulated 4AP in the first 7â¯days. Human Schwann cells showed elevated expression of key proteins such as nerve growth factor, myelin protein zero, and brain derived neurotrophic factor in a 4AP dose dependent manner. Preliminary in vivo studies in a critical-sized sciatic nerve defect in Wistar rats confirmed conduit suturability and strength to withstand ambulatory forces over 4â¯weeks of their implantation. Histological evaluations suggest conduit biocompatibility and Schwann cell infiltration and organization within the conduit and lumen. These nerve guidance conduits and 4AP sustained delivery may serve as an attractive strategy for nerve repair and regeneration.
Subject(s)
4-Aminopyridine/administration & dosage , Chitosan/administration & dosage , Drug Delivery Systems , Nanotubes , Nerve Regeneration/drug effects , Potassium Channel Blockers/administration & dosage , Sciatic Nerve/drug effects , 4-Aminopyridine/chemistry , Animals , Cell Survival/drug effects , Cells, Cultured , Chitosan/chemistry , Clay , Drug Liberation , Elastic Modulus , Female , Humans , Nanotubes/chemistry , Potassium Channel Blockers/chemistry , Rats, Wistar , Schwann Cells/drug effects , Sciatic Nerve/injuries , Sciatic Nerve/physiology , Tensile StrengthABSTRACT
Herein we report silver(i) directed infinite coordination polymer network (ICPN) induced self-assembly of low molecular weight organic ligands leading to metallogelation. Structurally simple ligands are derived from 3-aminopyridine and 4-aminopyridine conjugates which are composed of either pyridine or 2,2'-bipyridine cores. The cation specific gelation was found to be independent of the counter anion, leading to highly entangled fibrillar networks facilitating the immobilization of solvent molecules. Rheological studies revealed that the elastic storage modulus (G') of a given gelator molecule is counter anion dependent. The metallogels derived from ligands containing a bipyridine core displayed higher G' values than those with a pyridine core. Furthermore, using single crystal X-ray diffraction studies and 1H-15N two-dimensional (2D) correlation NMR spectroscopy, we show that the tetracoordination of silver ions enables simultaneous coordination polymerization and metallosupramolecular cross-linking. The resulting metallogels show spontaneous, in situ nanoparticle (d < 2-3 nm) formation without any additional reducing agents. The silver nanoparticle formation was followed using spectroscopic studies, and the self-assembled fibrillar networks were imaged using transmission electron microscopy (TEM) imaging.
Subject(s)
4-Aminopyridine/chemistry , Gels/chemistry , Metal Nanoparticles/chemistry , Silver/chemistry , Cross-Linking Reagents/chemistry , Polymerization , RheologyABSTRACT
Dalfampridine is a medication that is approved by the US Food and Drug Administration to improve walking impairments in patients with multiple sclerosis (MS). The branded dalfampridine is enormously expensive; hence, the availability of generic dalfampridine will provide better access to the medication, especially for uninsured patients with MS. Bioequivalence studies are demanded by the regulatory authorities to allow the marketing of new generics of dalfampridine. The aim of this study was to assess the bioavailability of the generic (test) and branded (reference) formulations of 10 mg dalfampridine of extended-release tablets after oral administration to healthy adults under fed conditions. The current report methodology was based on a comparative, randomized, single-dose, 2-way crossover open-label study design. Twenty-seven subjects were given a single dose of the test dalfampridine tablet and completed the clinical study. The pharmacokinetic parameters Cmax and AUC0ât, Kel , AUC0â∞ , tmax , and t1/2el were estimated to prove bioequivalence. The confidence intervals for the log-transformed test/reference ratios for dalfampridine 100.96% (97.09%-104.97%) and 99.77% (95.81%-103.87%) for Cmax and AUC0â∞ , respectively, were within the allowed limit specified by the regulatory authorities (80%-125%). Hence, clinically, the test tablet can be prescribed as an alternative to the reference for the indication of improving walking impairments in patients with MS.
Subject(s)
4-Aminopyridine/pharmacokinetics , Drugs, Generic/pharmacokinetics , Mobility Limitation , Potassium Channel Blockers/pharmacokinetics , 4-Aminopyridine/blood , 4-Aminopyridine/chemistry , Administration, Oral , Adult , Area Under Curve , Biological Availability , Cross-Over Studies , Delayed-Action Preparations , Drug Compounding , Drugs, Generic/chemistry , Healthy Volunteers , Humans , Male , Middle Aged , Multiple Sclerosis/drug therapy , Potassium Channel Blockers/blood , Potassium Channel Blockers/chemistry , Tablets , Therapeutic Equivalency , Young AdultABSTRACT
Central nervous system (CNS) demyelination represents the pathological hallmark of multiple sclerosis (MS) and contributes to other neurological conditions. Quantitative and specific imaging of demyelination would thus provide critical clinical insight. Here, we investigated the possibility of targeting axonal potassium channels to image demyelination by positron emission tomography (PET). These channels, which normally reside beneath the myelin sheath, become exposed upon demyelination and are the target of the MS drug, 4-aminopyridine (4-AP). We demonstrate using autoradiography that 4-AP has higher binding in non-myelinated and demyelinated versus well-myelinated CNS regions, and describe a fluorine-containing derivative, 3-F-4-AP, that has similar pharmacological properties and can be labeled with 18F for PET imaging. Additionally, we demonstrate that [18F]3-F-4-AP can be used to detect demyelination in rodents by PET. Further evaluation in Rhesus macaques shows higher binding in non-myelinated versus myelinated areas and excellent properties for brain imaging. Together, these data indicate that [18F]3-F-4-AP may be a valuable PET tracer for detecting CNS demyelination noninvasively.
Subject(s)
4-Aminopyridine/administration & dosage , Demyelinating Diseases/diagnostic imaging , Fluorine Radioisotopes/chemistry , Positron-Emission Tomography/methods , Potassium Channels/metabolism , 4-Aminopyridine/chemistry , 4-Aminopyridine/pharmacology , Animals , Demyelinating Diseases/metabolism , Female , Humans , Macaca mulatta , Male , Mice , Radioactive Tracers , RatsABSTRACT
4-Aminopyridine is a clinically approved drug to improve motor symptoms in multiple sclerosis. A fluorine-18-labeled derivative of this drug, 3-[18 F]fluoro-4-aminopyridine, is currently under investigation for positron emission tomography (PET) imaging of demyelination. Herein, the Yamada-Curtius reaction has been successfully applied for the preparation of this PET radioligand with a better radiochemical yield and improved specific activity. The overall radiochemical yield was 5 to 15% (n = 12, uncorrected) with a specific activity of 37 to 148 GBq/µmol (end of synthesis) in a 90 minute synthesis time. It is expected that this 1 pot Yamada-Curtius reaction can be used to prepare similar fluorine-18-labeled amino substituted heterocycles.
Subject(s)
4-Aminopyridine/chemistry , Fluorine Radioisotopes/chemistry , Radiopharmaceuticals/chemical synthesis , Automation/instrumentation , Automation/methods , Chemistry Techniques, Synthetic/instrumentation , Chemistry Techniques, Synthetic/methods , Positron-Emission Tomography/methodsABSTRACT
Carbon electrodes were functionalized through the reduction of diazopyridinium cations that are produced from in situ diazotization of 2-, 3- and 4-aminopyridine. Diazopyridinium salts were much more rarely employed for surface functionalization than other aryldiazonium derivatives. A study combining X-ray Photoelectron Spectroscopy (XPS), contact angle, ellipsometry, Atomic Force Microscopy (AFM) measurements and electrochemical analyses demonstrates that films obtained from 4-diazopyridinium cations are hydrophilic, dense, compact but sufficiently thin to preserve fast electronic transfer rate, being then relevant to efficiently tailor the interface between the anode surface and an electroactive biofilm. Microbial Fuels Cells (MFCs) with pyridine-functionalized graphite anodes exhibit faster development and improved performances than MFCs operating with bare graphite anodes.
Subject(s)
4-Aminopyridine/chemistry , Bioelectric Energy Sources/microbiology , Biofilms/growth & development , Carbon/chemistry , Pyridinium Compounds/chemistry , Cations/chemistry , Electrodes , Electron Transport , Electroplating , Equipment Design , Graphite/chemistry , Oxidation-Reduction , Surface PropertiesABSTRACT
Catalyst-mediated protein modification is a powerful approach for the imaging and engineering of natural proteins. We have previously developed affinity-guided 4-dimethylaminopyridine (AGD) chemistry as an efficient protein modification method using a catalytic acyl transfer reaction. However, because of the high electrophilicity of the thioester acyl donor molecule, AGD chemistry suffers from nonspecific reactions to proteins other than the target protein in crude biological environments, such as cell lysates, live cells, and tissue samples. To overcome this shortcoming, we here report a new acyl donor/organocatalyst system that allows more specific and efficient protein modification. In this method, a highly nucleophilic pyridinium oxime (PyOx) catalyst is conjugated to a ligand specific to the target protein. The ligand-tethered PyOx selectively binds to the target protein and facilitates the acyl transfer reaction of a mild electrophilic N-acyl-N-alkylsulfonamide acyl donor on the protein surface. We demonstrated that the new catalytic system, called AGOX (affinity-guided oxime) chemistry, can modify target proteins, both in test tubes and cell lysates, more selectively and efficiently than AGD chemistry. Low-background fluorescence labeling of the endogenous cell-membrane proteins, carbonic anhydrase XII and the folate receptor, in live cells allowed for the precise quantification of diffusion coefficients in the protein's native environment. Furthermore, the excellent biocompatibility and bioorthogonality of AGOX chemistry were demonstrated by the selective labeling of an endogenous neurotransmitter receptor in mouse brain slices, which are highly complicated tissue samples.
Subject(s)
Oximes/chemistry , Proteins/analysis , Staining and Labeling/methods , 4-Aminopyridine/analogs & derivatives , 4-Aminopyridine/chemistry , A549 Cells , Acylation , Animals , Brain Chemistry , Carbonic Anhydrases/analysis , Folate Receptors, GPI-Anchored/analysis , HEK293 Cells , HeLa Cells , Humans , Membrane Proteins/analysis , Mice , Receptors, Neurotransmitter/analysisABSTRACT
The application of six novel α,ß-dipeptides as chiral organocatalysts in the asymmetric Michael addition reaction between enolizable aldehydes and N-arylmaleimides or nitroolefins is described. With N-arylmaleimides as substrates, the best results were achieved with dipeptide 2 as a catalyst in the presence of aq. NaOH. Whereas dipeptides 4 and 6 in conjunction with 4-dimethylaminopyridine (DMAP) and thiourea as a hydrogen bond donor proved to be highly efficient organocatalytic systems in the enantioselective reaction between isobutyraldehyde and various nitroolefins.
Subject(s)
Dipeptides/chemistry , 4-Aminopyridine/analogs & derivatives , 4-Aminopyridine/chemistry , Aldehydes/chemistry , Alkenes/chemistry , Catalysis , Hydrogen Bonding , Maleimides/chemistry , Nitro Compounds/chemistry , Solvents , Stereoisomerism , Thiourea/chemistryABSTRACT
Neuroprotection refers to the relative preservation of neuronal structure and function. Neuroprotective agents refer to substances that are capable of preserving brain function and structure. Currently, there are no neuroprotective agents available that can effectively relieve the progression of Parkinson's disease. In this work, five novel 4-aminopyridine derivatives, including three amides and two ureas, were designed, synthesized, and evaluated using the rat PC12 mice pheochromocytoma cell line as an in vitro model. As well as human Rho kinase inhibitory experiment was performed. Among them, compound 3, which exhibited high cell viability, low cytotoxicity and good efficacy of inhibition on α-synuclein, oxidation, inflammation and Rho kinase, was profound as potential agents for Parkinson's disease (PD).
Subject(s)
4-Aminopyridine/pharmacology , Drug Design , Molecular Docking Simulation , Neuroprotective Agents/pharmacology , Parkinson Disease/drug therapy , Protein Kinase Inhibitors/pharmacology , 4-Aminopyridine/chemical synthesis , 4-Aminopyridine/chemistry , Animals , Cell Proliferation/drug effects , Cell Survival/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Humans , Immunohistochemistry , Molecular Structure , Neuroprotective Agents/chemical synthesis , Neuroprotective Agents/chemistry , PC12 Cells , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/chemistry , Rats , Structure-Activity Relationship , alpha-Synuclein/antagonists & inhibitors , alpha-Synuclein/metabolism , rho-Associated Kinases/antagonists & inhibitors , rho-Associated Kinases/metabolismABSTRACT
In controlled porosity osmotic pumps (CPOP), usually finding a single solvent with a capability to dissolve both film former (hydrophobic) and pore former (hydrophilic) is extremely challenging. Therefore, the aim of the present investigation was to tackle the issue associated with controlled porosity osmotic pump (CPOP) system using nano-suspension coating method. In the present study 4-Amino pyridine was used as a highly water soluble drug. In this method, a hydrophilic pore former (sucrose or mannitol) in nano range was suspended in polymeric coating solution using ball-mill. The performance of the prepared formulations was assessed in terms of D12h (cumulative release percent after 12h), Devzero (mean percent deviation of drug release from zero order kinetic), tL (lag time of the drug release) and RSQzero. The results revealed that gelling agent amount (HPMC E15LV) in core and pore former concentration in SPM had crucial effect on SPM integrity. All the optimised formulations showed a burst drug release due to fast dissolving nature of the pore formers. Results obtained from scanning electron microscopy demonstrated the formation of nanopores in the membrane where the drug release takes place via these nanopores. Nano suspension coating method can be introduced as novel method in formulation of CPOPs.
Subject(s)
4-Aminopyridine/chemistry , Drug Delivery Systems , Drug Liberation , Nanotechnology/methods , Osmosis , Hydrophobic and Hydrophilic Interactions , Particle Size , Porosity , Solubility , Surface Properties , Suspensions/chemistryABSTRACT
Chromium(III) chlorido amine-bis(phenolate) complexes paired with nucleophilic co-catalysts are a promising family of catalysts for the copolymerization of CO2 and epoxides to selectively produce polycarbonates with a very high degree of carbonate linkages. Single-component catalyst systems can be prepared, where the neutral nucleophile, 4-dimethylaminopyridine (DMAP), is coordinated to the metal site to provide a stable octahedral CrIII complex. These complexes possess the potential for both anionic (from the chlorido ligand) or neutral (DMAP) nucleophilic epoxide ring-opening during the proposed rate-determining initiation step. Concentration effect studies support a first-order dependence of the polymerization rate on the concentration of single-component catalyst. End-group analysis of polycarbonates by MALDI-TOF MS indicate the presence of predominantly DMAP-initiated chains as well as the occurrence of chain-transfer events resulting in ether linkages, likely from the presence of cyclohexene diol formed by the reaction of cyclohexene oxide and adventitious water.
Subject(s)
4-Aminopyridine/analogs & derivatives , Carbon Dioxide/chemistry , Chromium/chemistry , Cyclohexenes/chemistry , Organometallic Compounds/chemistry , Polymerization , 4-Aminopyridine/chemistry , CatalysisABSTRACT
Pogostone, isolated from Pogostemon cablin, has many biological activities such as potential antibacterial, anticandida, and antifungal. Traditional extraction leads to low output of PO about 17.6 mg/kg from Herba Pogostemonis. The previous literature had reported a synthetic study and the yield had reached 4.48% with strictly controlled reaction conditions. The two methods above cannot meet the large demand of PO; we report a new synthesis method. 4-hydroxy-6-methyl-2-pyrone (1) was added in toluene, with the existence of acylation catalyst 4-dimethylaminopyridine (DMAP), 4-methylvaleric acid (2), and condensing agent dicyclohexylcarbodiimide (DCC), PO was synthesized after the combination of 3-carbon of (1) with 1-OH of (2) in the acylation reaction. The purity had reached 98%, determined by HPLC. The structure was confirmed by spectroscopic methods including infrared, electron ionization mass spectrometry, and nuclear magnetic resonance spectroscopy. PO was totally synthesized in one step including cyclization, with total yield of 27.2%.